Dose-escalation Study of Afatinib in Elderly Patients with EGFR mutation for Non-Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 18 Oct 2017 Results assessing the maximum tolerated dose (MTD), recommended phase II dose of afatinib in elderly patients with advanced NSCLC harboring EGFR mutations, were presented at the 18th World Conference on Lung Cancer.
- 31 Oct 2016 Status changed from active, no longer recruiting to completed.
- 28 Aug 2016 Status changed from recruiting to active, no longer recruiting.